"There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives.  This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.  We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine.  This might be a therapy to treat an extremely rare and life-threatening disease like Hunter syndrome or Fabry disease; or a medicine for a specialist condition like ADHD or ulcerative colitis; or a treatment to help the healing of diabetic foot ulcers which if not treated effectively, can dramatically affect the lives of the patient and their whole family.

Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients". 

Link: www.shire.com/shireplc/en/about/aboutshire